ALK-Abelló A/S
Denmark · DK0061802139 · reports in DKK · Europe
Four figures
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Revenue growth
- Revenue +14% in the year to Dec 31, 2025, on the year before.
- Return on equity
- It earned 19% on its shareholders' equity in the year to Dec 31, 2025.
- Equity and assets
- Equity is 71% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in DKK.
DKK 6.3B
revenue
26%
operating margin
DKK 1.2B
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | DKK 4.5B | DKK 4.8B | DKK 5.5B | DKK 6.3B |
| Operating profit | DKK 470M | DKK 666M | DKK 1.1B | DKK 1.7B |
| Earnings per share | DKK 1.52 | DKK 2.20 | DKK 3.68 | DKK 540.00 |
| Cash from operations | DKK 416M | DKK 667M | DKK 1.2B | DKK 1.8B |
| Capital spending | DKK 298M | DKK 310M | DKK 260M | DKK 276M |
| Cash | n/a | n/a | DKK 589M | DKK 1.2B |
| Total assets | DKK 6.3B | DKK 6.7B | DKK 8.2B | DKK 9.1B |
| Equity | DKK 4.0B | DKK 4.4B | DKK 5.4B | DKK 6.4B |
What they do
In the company's own words, from the annual report.
ALK is a global allergy solutions company
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.